Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Devimistat,Gemcitabine,Cisplatin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Cornerstone Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CPI-613® (devimistat) is a first-in-class clinical lead compound of Cornerstone, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Brand Name : CPI-613
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2022
Lead Product(s) : Devimistat,Gemcitabine,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Cornerstone Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
